

Sponsored Projects: Padmashree Dr D Y Patil Medical College, Hospital & Research Center, Navi Mumbai 400706

Sr No	Title of Clinical Trial Study	Principle Investigator	Sponsored by	Total Funding
1	Evaluation of Typhoid Conjugate Vaccine(TCV) introduction program-Navi Mumbai, India (PI Dr Rajesh Rai, Professor & Head, Department of Pediatrics)	Dr Rajesh Rai	WHO- India, CDC-Atalanta & Stanford University, USA	
2	A Phase III, multicenter, randomized, observer blind, parallel group, three arm, controlled clinical trial to evaluate the efficacy and safety of topically applied Calocipotriol / AKV ANO 50 µg/g Cutaneous solution against Diavonex® 50 µg/g Crème, LEO and placebo in patients with mild to moderate plaque psoriasis.	Dr Sharmila Patil, Department of Dermatology	Cadila Pharmaceuticals	
3	Pharmacodynamic (PD) Study to demonstrate the equivalence of Sevelamer Hydrochloride Tablets 800 mg (Test Drug) with Renagel Tablets 800 mg (Reference Drug) in patients of Hyperkalemia receiving Hemodialysis	Dr Avinash Chaudhary, Kidney Dialysis Department.	Cadila Pharmaceuticals	891,000/-
4	A Prospective, Randomized, Parallel group Study to Evaluate the Safety and Efficacy of FDC of Mupirocin calcium, Neomycin Sulfate & HT61 HCL in Patients with infected skin lesions by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) and/or S. Pyogenes.	Dr. Sharmila Patil, Department of Dermatology	Cadila Pharmaceuticals	22,000/-
5	A prospective, observational, post marketing surveillance study to evaluate the effectiveness and safety of	Dr Kiran Godse, Department of	Novartis	88,000/-
6	A Phase III, Randomized, Open-Label, Multiple-Dose, Parallel-Group Study to Determine Efficacy, Safety, Pharmacokinetics and Immunogenicity of Recombinant Human FSH of Cadila Healthcare Limited, India as compared to Gonal-FTM Administered Subcutaneously in Female Patients Undergoing Assisted Reproductive Technology.	Dr Pallavi Vishwekar, Department of OBGY	Cadila Pharmaceuticals	2,22,000/-

Sponsored Projects: Padmashree Dr D Y Patil Medical College, Hospital & Research Center, Navi Mumbai 400706

Sr No	Title of Clinical Trial Study	Principle Investigator	Sponsored by	Total Funding
7	A Randomized, Double Blind, Placebo Controlled, Three Arm, Parallel Group, Multicentric Clinical Study to Evaluate the Therapeutic Bioequivalence of Two tacrolimus 0.03% Topical Ointment Formulations In Adult Patients With Moderate To Severe Atopic Dermatitis.	Dr. Sharmila Patil, Department of Dermatology	Intas Pharmaceuticals	1,001,000/-
8	Open Label, Randomized, Multicentric, Two Treatments, Single Dose, Parallel Group, Bioequivalence Study Of Test Leteprednol Etabonate Ophthalmic Suspension 0.5%, Manufactured By Indoco Remedies Ltd., For Watson Pharma Pvt Ltd. With Reference LOTEMAX® (Leteprednol Etabonate Ophthalmic Suspension 0.5%) Manufactured By Bausch And Lomb Inc. In Aqueous Humor Of Patients Undergoing Indicated Cataract Surgery.	Dr. Nita Shanbhag Department of Ophthalmology	Indoco Remedies Ltd	--
9	Open Label Clinical Study To Determine The Specificity And Sensitivity Of Algorithm (Software) Developed By Bosch Using Bosch Mobile Non-Mydriatic Fundus Camera Comparing It With Mydriatic 7- Standard Field Stereoscopic Digital Color Fundus Photography (EDTRS) Done In Patients In Undiagnosed Diabetic Retinopathy (Symptomatic/Asymptomatic)	Dr Nita Shanbhag, Department of Ophthalmology	Bosch	--
10	An Open Label, Prospective, Single Arm Study to Evaluate Safety and Efficacy Of Heme – Iron In Pregnant Women.	Dr Shriram Gopal, Department of Obgy	Wockhardt Pharmaceuticals	--
11	A prospective, post marketing surveillance study to study the safety and effectiveness of Omalizumab in Indian patients with Chronic Spontaneous Urticaria refractory to standard of care.	Dr. Kiran Godse, Prof and Head, Dept of Dermatology.	Novartis	1,848,000/-

Sponsored Projects: Padmashree Dr D Y Patil Medical College, Hospital & Research Center, Navi Mumbai 400706

Sr No	Title of Clinical Trial Study	Principle Investigator	Sponsored by	Total Funding
12	An open label, prospective, comparative, assessor blind, single centric study for evolution of tolerability and efficacy	Dr. Kiran Godse, Prof, Dept of Dermatology	Wockhardt Pharmaceuticals	21,000/-
13	An open label, prospective, comparative, multicenter, two weeks study to assess the device handling, human factors, ease of use, errors & participant perception on use of Synchrobreath- a breath actuated inhaler versus pressurized metered dose inhaler in healthy volunteers & in patients with Asthma or COPD	Dr Keya Lahiri, Department of Pediatrics	Cipla Pharmaceuticals	80,000/-
14	Registry in the Management of Acute Diarrhea in children: Observational study in daily practice 2(REMAD 2)	Dr Keya Lahiri, Department of Pediatrics	Sanofi Pharmaceuticals	135000/-
15	A Multicentre, double blinded, active controlled, parallel group, two arm, bioequivalence study with clinical end point comparing Brinzolamide 1% ophthalmic suspension (manufactured by Indoco Remedies Ltd) to Brinzolamide 1 % suspension (Azopt@, manufactured by Alcon Laboratories) , in the treatment of chronic open angle glycoma or ocular hypertension in both eyes.	Dr Neeta Shanbhag, Department of Ophthalmology	Alcon Laboratories	3,33,000/-
16	A randomized, double blind, double dummy, placebo with controlled, multi-center study of Secukinumab to demonstrate efficacy after 12 weeks of treatment compared to placebo, etanercept & to access the safety, tolerability & long time efficacy up to 1 year in subjects with moderate to severe chronic plaque type psoriasis.	Dr. Sharmila Patil, Prof and Head, Dept of Dermatology	Novartis Pharmaceuticals	27,000/-
17	An open label, non-comparative, multicenter, phase IV study to evaluate the safety and efficacy of TINEFCON in subjects with plaque psoriasis	Dr. Sharmila Patil, Prof and Head, Dept of Dermatology	Primal Pharmaceuticals	195,000/-
Total: Rs. Forty Eight Lakhs Sixty Three Thousands only				48,63,000/-